Key result
The CYP11B2 -344C/T polymorphism in the recessive model was significantly associated with an increased risk of all subtypes of chronic glomerulonephritis (OR 1.925; 95% CI 1.152-3.219; p=0.0118).
Why the study?
Are AGT M235T, ACE (I/D), and CYP11B2 -344C/T polymorphisms associated with the risk of primary chronic glomerulonephritis in the Polish population?
Case-Control (n=327)
Are AGT M235T, ACE (I/D), and CYP11B2 -344C/T polymorphisms associated with the risk of primary chronic glomerulonephritis in the Polish population?
Effect estimate: OR 1.925 (95% CI 1.152-3.219)
p-value: p=0.0118
The CYP11B2 -344C/T polymorphism may be an independent genetic risk factor for primary chronic glomerulonephritis, particularly IgA nephropathy and focal segmental glomerulosclerosis, in the Polish population.
May support genetic risk assessment in Polish glomerulonephritis; leaves open prospective validation before clinical adoption.
INTRODUCTION: We evaluate whether angiotensinogen AGT M235T (rs699), angiotensin-converting enzyme ACE (I/D) (rs4646994) and aldosterone synthase CYP11B2 -344C/T (rs1799998) polymorphisms can be genetic risk factors of chronic glomerulonephritis (GN) in the Polish population. MATERIALS AND METHODS: The study was conducted in 140 patients with primary chronic GN: mesangial proliferative GN (MesPGN) (n = 49), IgA nephropathy (IgAN) (n = 31), membranous nephropathy (MN) (n = 27), focal segmental glomerulosclerosis (FSGS) (n = 25), membranoproliferative GN (MPGN) (n = 4), and minimal change disease (MCD) (n = 4), and controls (n = 187). Genotypes were determined by HRM curve analysis for AGT M235T, by PCR and agarose gel separation for ACE (I/D), and by PCR-RFLP for CYP11B2 -344C/T. RESULTS: We found a significant association of the CYP11B2 -344C/T polymorphism in the recessive model with all subtypes of GN (OR = 1.925 (95% CI = 1.152-3.219, p = 0.0118, p(corr) = 0.0354)). We also observed that the CYP11B2 -344C/T polymorphism in the recessive model may also be an independent significant risk factor of IgAN (OR = 2.743 (95% CI = 1.219-6.172, p = 0.0122, p(corr) = 0.0366)), FSGS (OR = 2.895 (95% CI = 1.200-6.985, p = 0.0145, p(corr) = 0.0435)), and all proliferative GNs (MesPGN, IgAN, MPGN) (OR = 2.171 (95% CI = 1.211-3.894, p = 0.0084, p(corr) = 0.0252)). CONCLUSION: Our results suggest that the CYP11B2 -344C/T polymorphism might be an independent risk factor of IgAN, FSGS and all proliferative chronic GNs.
No takes yet. Share an insight, caveat, or question.
Pawlik et al. (2013) conducted a case-control in Primary chronic glomerulonephritis (n=327). CYP11B2 -344C/T polymorphism vs. Controls was evaluated on Risk of all subtypes of chronic glomerulonephritis (OR 1.925, 95% CI 1.152-3.219, p=0.0118). The CYP11B2 -344C/T polymorphism in the recessive model was significantly associated with an increased risk of all subtypes of chronic glomerulonephritis (OR 1.925; 95% CI 1.152-3.219; p=0.0118).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: